A Dutch biotech company, founded in 2020, has raised €39 million in Series A financing to accelerate development of a preclinical compound that targets blood clots in order to treat acquired thrombotic thrombocytopenia purpura (aTTP) and acute ischaemic stroke. TargED Biopharmaceuticals BV is a spin-out of the University Medical Center in the Netherlands. Its top management all have experience in blood disorders.
The financing round was arranged by an international syndicate comprising Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures.